<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1977">
  <stage>Registered</stage>
  <submitdate>20/05/2008</submitdate>
  <approvaldate>20/05/2008</approvaldate>
  <nctid>NCT00681226</nctid>
  <trial_identification>
    <studytitle>Angiotensin Converting Enzyme (ACE) Inhibition and Peripheral Arterial Disease</studytitle>
    <scientifictitle>ACE Inhibition; A Potential New Therapy for Peripheral Arterial Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>273/06</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Arterial Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ramipril or matching placebo

Treatment: drugs: Ramipril or matching placebo
10 mg Ramipril or matching placebo once daily for 6 months

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>walking time</outcome>
      <timepoint>baseline and 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>walking impairment questionnaire</outcome>
      <timepoint>baseline and 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Ankle brachial index of &lt;0.9 in at least one leg

          -  History of intermittent claudication (unilateral or bilateral)

          -  A stable medication regimen for at least 6 months</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Limiting coronary artery disease

          -  Renal failure (serum creatinine &gt; 0.20 mmol/L)

          -  Current treatment or treatment within the previous 6 months with ACE inhibitors or
             angiotensin II receptor antagonists</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>200</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Baker Heart Research Institute - Melbourne</hospital>
    <postcode>8008 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Bayside Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Leg pain caused by peripheral arterial disease (PAD) can severely impede walking ability. Our
      preliminary findings indicate that the drug ramipril is much more effective in improving
      walking ability than current therapies. To be accepted as a new treatment for PAD these
      findings require validation in a much larger clinical trial.We propose to examine the effects
      of ramipril therapy for 6 months in a randomized, controlled trial of patients with PAD. If
      positive, this study will identify ramipril as a potential new therapy for PAD.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00681226</trialwebsite>
    <publication>Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006 May 2;144(9):660-4. Retraction in: Ann Intern Med. 2015 Dec 1;163(11):884.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bronwyn A Kingwell, PhD</name>
      <address>Baker Heart Research Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>